Is This Microneedling Device Cleared to Deliver PRP?

Is this device cleared to deliver PRP?

When scheduling a microneedling procedure marketed as a "vampire facial" or booking a treatment packaged with platelet-rich plasma (PRP), multivitamin infusions, growth-factor serums, or micro-droplets of dermal filler, patients routinely encounter clinic websites claiming the service features an "FDA-approved microneedling pen." This marketing language creates an understandable, reassuring impression: that federal medical regulators have reviewed and validated the entire procedure—specifically the practice of driving biological fluids, vitamins, or pharmacological compounds through open needle punctures into living facial tissue.

That impression does not match FDA's legally marketed uses or the delivery sentences on the patient and consumer-update pages. The U.S. Food and Drug Administration has granted marketing authorization to a limited number of powered microneedling devices, but those authorizations are restricted to mechanical puncture and injury of skin tissue for specific dermatologic indications such as facial acne scars, facial wrinkles, and abdominal scars in adults aged 22 years and older. The FDA has not cleared or approved any microneedling medical device for the transdermal delivery of PRP, topical drugs, cosmetic cocktails, or dermal fillers into the skin.

"Microneedling devices are not approved for delivery of cosmetics, topical medications (for example, creams, ointments, gels), vitamin solutions, drugs, or blood products (for example, platelet-rich plasma (PRP)) into the skin."

— U.S. Food and Drug Administration, Microneedling Devices (Information for Patients), current as of October 15, 2025

On the same Microneedling Devices page, in the risks section rather than as a continuation of that patient sentence, FDA states: "The risks associated with other uses ('off label uses') of microneedling devices, the combination of microneedling devices with other products, or the use of microneedling products that have not been evaluated by the FDA are not known."

On the same date, the agency reaffirmed this stance in its consumer safety update, clarifying the regulatory standard in clearance terminology:

"You may be aware of microneedling products used along with creams, ointments, other drugs or cosmetics, or platelet-rich plasma. The FDA has not cleared any microneedling devices for use with another product, which means the FDA hasn’t reviewed the safety or effectiveness of combining microneedling devices with other products."

— U.S. Food and Drug Administration, Microneedling Devices: Getting to the Point on Benefits, Risks, and Safety, October 15, 2025

A menu title is not a delivery authorization. Mark this labeled fictional appointment through three independent regulatory identities:

1. Device Identity: What exact instrument is being placed against your face? Is it an FDA-cleared Class II powered microneedling pen (under product code QAI), a radiofrequency (RF) energy device, a non-medical cosmetic roller that cannot legally penetrate living skin, an autologous blood centrifuge, or an unbranded import lacking any federal authorization?

2. Delivery Identity: What substance is being placed on your skin during or immediately after the procedure? Is it an authorized inert hydrogel lubricant (such as Lift HG), or is the clinician attempting to force autologous PRP, vitamins, botulinum toxin, or hyaluronic acid filler into the microscopic wound channels?

3. Cartridge Identity: Is the needle assembly a brand-new, factory-sealed, single-use sterile cartridge opened in your presence, or is the clinic reusing, autoclaving, or cleaning disposable tips across patients or multiple treatment sessions?

Identity worksheet: device, substance, cartridge, and unknown fields

Before signing an informed consent form or allowing a provider to initiate treatment, you should verify the three core identity fields. Many clinical intake packets conflate device clearance with procedure safety. To assist in that evaluation, the following flowchart maps the three distinct verification gates every appointment must pass.

flowchart TD
  Start["Patient Appointment Audit"] --> Gate1{"Gate 1: Device Identity"}
  Gate1 -- "Class II QAI Mechanical Pen" --> CheckIndication["Verify Cleared Anatomical Indication (Scars / Wrinkles)"]
  Gate1 -- "RF Energy Device" --> NoteRF["Different Technology (Electrodes / Thermal Heating)"]
  Gate1 -- "Non-Penetrating Roller" --> NoteRoller["Cosmetic Exfoliation Only (Not a Medical Device)"]
  Gate1 -- "ORG Centrifuge" --> NoteCentrifuge["Blood Separation Only (Bone Graft Handling)"]
  Gate1 -- "Unbranded / Unknown" --> RedFlag1["Red Flag: Unverified Device"]

  CheckIndication --> Gate2{"Gate 2: Planned Substance"}
  Gate2 -- "Inert Hydrogel (Lift HG) or None" --> AuthorizedPuncture["Cleared Mechanical Puncture Use"]
  Gate2 -- "PRP / Blood Product" --> OffLabelPRP["Off-Label Combination: Not Cleared for Delivery"]
  Gate2 -- "Vitamins / Drugs / Fillers" --> OffLabelDrug["Off-Label Combination: Unknown Risks"]

  AuthorizedPuncture --> Gate3{"Gate 3: Cartridge Sterility"}
  OffLabelPRP --> Gate3
  OffLabelDrug --> Gate3

  Gate3 -- "Brand-New Sealed Single-Use" --> SterilityPass["Sterility Met (Does Not Authorize Delivery)"]
  Gate3 -- "Reused / Cleaned / Unknown" --> SterilityFail["Reuse unsafe / not consistent with FDA authorization"]

The decision table below provides eight substantive, clearly labeled hypothetical appointment scenarios. It demonstrates how trade names, clearance records, topical substances, and needle cartridges interact under federal law. Notice how a positive mark in one column never guarantees authorization in another.

To use this worksheet during an actual consultation, ask your clinician to confirm each item directly from the physical packaging and regulatory documents:

• Check the Device Handpiece: Inspect the manufacturer label on the handpiece or base station. Match the printed trade name to a QAI De Novo or 510(k) summary, such as SkinPen Precision, Exceed, SkinStylus SteriLock, or MicroPen EVO. A CE mark is not a U.S. marketing authorization. If the device is unnamed or no review number is visible, mark the device unknown.

• Inspect the Topically Applied Fluid: Ask what exact substance will be in contact with your skin while the motorized needles are active. If the provider uses autologous PRP, a vitamin cocktail, a topical drug, or dermal filler, that delivery is not an FDA-authorized microneedling use, and combination-use risks are not known. A labeled SkinPen kit uses Lift HG hydrogel without drugs or biologics, not PRP.

• Watch the Needle Cartridge Unsealing: FDA tells patients to ask whether a new microneedle cartridge is used for each patient and for each treatment session for the same patient. Reuse is a separate identity from delivery: a new cartridge does not authorize PRP, and a reused or unknown cartridge is not proof the pen is authorized to deliver PRP. Packaging and lot-code inspection belong to the published cartridge-sterility article.

What FDA has actually authorized the pen to do

To understand why microneedling devices cannot deliver PRP or drugs, one must examine the specific statutory regulation that governs them. In the Code of Federal Regulations, aesthetic microneedling instruments are classified under 21 CFR 878.4430, officially titled "Microneedling device for aesthetic use." Codified by FDA in June 2018 (83 FR 26577), the regulation establishes a precise identification:

"A microneedling device for aesthetic use is a device using one or more needles to mechanically puncture and injure skin tissue for aesthetic use. This classification does not include devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biologics."

— 21 CFR § 878.4430(a), Title 21, Food and Drugs

The second sentence of that identification is the delivery boundary. FDA did not overlook transdermal delivery; it explicitly excluded any instrument intended to deliver cosmetics, pharmaceuticals, or biologics from the 21 CFR 878.4430 classification. Any device designed or promoted to inject, infuse, or drive topical products through the epidermal barrier falls under entirely different regulatory controls with substantially higher evidentiary hurdles.

Under 21 CFR 878.4430, microneedling devices for aesthetic use are designated as Class II medical devices subject to special controls. Those controls include identified needle length, geometry, maximum penetration depth, and puncture rate; performance data on needle-depth and puncture-rate accuracy, fluid-ingress protection against cross-contamination, and the maximum safe penetration depth; sterility and shelf-life of patient-contacting components; electrical safety and electromagnetic compatibility; software validation where applicable; biocompatibility of patient-contacting components; validated cleaning and disinfection of reusable components; and clinician and patient labeling. SkinPen's De Novo order also treats the system as a prescription device under 21 CFR 801.109. Those controls describe the classified mechanical-puncture type; they are not a delivery authorization.

It is also vital to distinguish 510(k) clearance and De Novo classification from Class III Premarket Approval (PMA). Medical spas frequently advertise that their microneedling pen is 'FDA-approved.' In federal regulatory terminology, 'approval' is reserved almost exclusively for high-risk Class III devices (such as cardiac pacemakers or permanent breast implants). Class II devices like microneedling pens receive marketing clearance through the 510(k) pathway or marketing authorization through a De Novo grant. Calling a pen 'FDA-approved' misstates the regulatory mechanism; calling it 'FDA-approved to deliver PRP' misstates both the mechanism and the legal scope of the device.

Primary-Source Lookup Examples

To see how these statutory limits appear in official public documentation, consider the clearance records for major Class II microneedling devices under product code QAI. These examples illustrate how to read an authorization—they do not constitute a ranked product list or an endorsement:

• SkinPen Precision System (DEN160029 & K202243): In March 2018, the FDA granted De Novo classification DEN160029 to Crown Aesthetics (Bellus Medical), creating product code QAI. The cleared indication was restricted to improving the appearance of facial acne scars in adults aged 22 years or older. The official De Novo Decision Summary explicitly warns: "This product is not intended for transdermal (under the skin) delivery of topical products such as cosmetics, drugs, or biologics." The cleared system consists strictly of the motorized handpiece, a single-use sterile cartridge, a disposable BioSheath, and Skinfuse Lift HG—an inert hydrogel lubricant. Traditional 510(k) K202243 reaffirmed these components and clinical evaluation with Lift HG, not blood products.

• Exceed Microneedling Device (K180778 & K182407): Manufactured by amiea med / MT.DERM GmbH, Exceed secured 510(k) clearance K180778 for the treatment of facial wrinkles in Fitzpatrick skin types I–III in glabellar frown lines, periorbital lines, and cheek folds in adults aged 22 and older. Clearance K182407 subsequently cleared the device for facial acne scars in Fitzpatrick skin types I–IV. Both summaries recite the statutory definition of 21 CFR 878.4430, confirming that the device is cleared for mechanical puncture only and excludes transdermal delivery.

• SkinStylus SteriLock MicroSystem (K200044): Cleared under 510(k) K200044, SkinStylus is indicated to improve the appearance of surgical or traumatic hypertrophic scars on the abdomen in adults aged 22 years or older, as well as facial acne scars in adults aged 22 years or older. The mode of action is explicitly defined as mechanical puncture and tissue injury; it confers no authorization for fluid delivery.

• Eclipse MicroPen EVO (K212558): Cleared under K212558 (predicated on SkinPen K202243), MicroPen EVO is authorized to improve the appearance of wrinkles of the neck for Fitzpatrick skin types II–IV and facial acne scars in all Fitzpatrick skin types aged 22 and older. Its indications remain strictly tied to mechanical injury.

• Manufacturer Safety Disclosures (Revance / Crown 2025): The shared Important Safety Information (ISI) published for SkinPen Precision Elite, SkinPen Precision, and MicroPen EVO states their dual indications (neck wrinkles and facial acne scars) and unambiguously warns clinicians and patients: "These products are not intended for transdermal (under the skin) delivery of topical products such as cosmetics, drugs, or biologics."

Delivery of PRP, vitamins, drugs, or filler is a different identity

How did the aesthetic industry transition from mechanical wound remodeling to the ubiquitous 'vampire facial'? The answer lies in a marketing concept known as "transdermal micro-channel delivery." Proponents argue that because motorized needles create many small puncture holes through the stratum corneum, clinicians should take advantage of this transient barrier disruption by smearing active biological substances across the skin, allowing them to seep deep into the dermis.

Puncture and delivery are different identities. When FDA legally authorized QAI microneedling devices, it reviewed data supporting a reasonable assurance of safety and effectiveness for specified scar or wrinkle uses produced by mechanical puncture. Those summaries do not convert the pen into a reviewed delivery system for PRP, vitamins, drugs, or filler.

The FDA did not evaluate what happens when foreign biological fluids, concentrated platelets, or pharmaceutical compounds are flooded into those open channels. FDA's patient page states that the risks associated with off-label uses, combining microneedling devices with other products, or using products that have not been evaluated by FDA are not known.

The Combination Product Barrier (21 CFR 3.2(e))

In November 2020, the FDA published comprehensive industry guidance entitled Regulatory Considerations for Microneedling Products (Document number 1500036). In that guidance, the FDA directly addressed the commercial trend of combining microneedling instruments with topicals:

"Microneedling products have also been promoted with topically applied substances such as creams, ointments, gels, vitamin solutions, drugs, or blood products (e.g., platelet-rich plasma), which may be packaged together with the microneedling product or available separately where the microneedling product provides instructions for use with such topical products. Such microneedling products may be combination products under 21 CFR 3.2(e), which would be regulated by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and/or the Center for Devices and Radiological Health (CDRH). Microneedling combination products are outside the scope of this guidance."

— FDA Guidance for Industry and Staff, Regulatory Considerations for Microneedling Products (November 2020)

FDA's November 2020 guidance says microneedling products promoted with topicals or blood products such as PRP may be combination products under 21 CFR 3.2(e), which would be regulated by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and/or the Center for Devices and Radiological Health (CDRH). Microneedling combination products are outside the scope of that guidance. This article's FDA records do not include a marketing authorization for a microneedling combination product that delivers PRP, cosmetics, vitamin solutions, drugs, or filler into the skin.

What Is Lift HG? (The Cleared Inert Lubricant)

If microneedling devices are cleared only for mechanical puncture, why does the SkinPen kit include a topical gel? In DEN160029 and K202243, the cleared kit includes Skinfuse Lift HG. It is essential that patients understand the exact regulatory identity of this substance:

• Regulatory Classification: Lift HG is a Class I, 510(k)-exempt hydrogel wound dressing classified under 21 CFR 878.4022 (product code NAE).

• Formulation: The De Novo decision summary identifies Lift HG as a hydrogel wound dressing without drugs and/or biologics. It is not PRP, a vitamin cocktail, or filler.

• Intended Purpose: DEN160029 describes Lift HG as protecting against abrasion and friction during the microneedling procedure, and notes that it may be applied to prevent skin from drying out after the procedure.

When a clinician sets aside Lift HG and replaces it with autologous PRP, a vitamin C serum, or a neurotoxin blend, they are not using a cleared kit accessory. They are replacing an inert Class I lubricant with an unreviewed biological or pharmaceutical agent.

Off-Label Practice vs False Advertising

In the United States, licensed physicians possess the legal discretion to practice medicine, which includes using legally marketed medical devices off-label according to their clinical judgment. A doctor can legally choose to perform microneedling and topically apply PRP. However, a provider's off-label legal discretion does not convert the procedure into an FDA-cleared use.

When a med spa advertises an 'FDA-cleared vampire facial' or tells a patient that 'our PRP microneedling system is fully FDA-approved,' they cross the line from clinical discretion into deceptive marketing. As the FDA made clear in October 2025, the risks of combining microneedling with other products are scientifically unknown.

A centrifuge 510(k) is not a pen 510(k)

One of the most common mix-ups encountered by prospective patients is the "centrifuge 510(k) mix-up." When a skeptical patient asks if their upcoming PRP microneedling treatment is FDA-cleared, the med spa staff will proudly display an official FDA 510(k) clearance letter. Upon closer inspection, however, that letter is almost invariably for the blood centrifuge or blood separation tube kit—not for the microneedling pen, and certainly not for the combined facial procedure.

Autologous blood cell separators are classified under 21 CFR 864.9245 as Class II hematology devices under product code ORG. Reviewing actual public 510(k) summaries reveals the stark disconnect between their legal clearance and their aesthetic marketing:

• Illuminate PRP System (BK241042): The FDA-hosted 510(k) summary for Illuminate PRP classifies the unit as an automated blood cell separator under 21 CFR 864.9245 (product code ORG). Its cleared indication states that it is intended for the safe and rapid preparation of autologous PRP from a small sample of peripheral blood at the patient point-of-care. Crucially, the clearance specifies that the resulting PRP is intended to be "mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics." It is an orthopedic bone-graft handling tool, not a facial rejuvenation license.

• Crown Aesthetics ProGen Platelet-Rich Plasma System: Crown Aesthetics manufactures the SkinPen microneedling device and also distributes the ProGen PRP kit. Clinics frequently market them as a matched pair. Yet the official ProGen intended-use footnote confirms the identical orthopedic limitation: rapid preparation of autologous PRP mixed with autograft or allograft bone prior to application to a bony defect. Corporate portfolio proximity does not merge regulatory clearances.

Using an ORG-cleared centrifuge to separate platelets simply means the machine has met FDA standards for separating blood components safely. It confers zero authorization to inject, puncture, or massage that plasma into facial skin with a QAI microneedling pen.

Distinguishing Other Instruments in the Clinic

During an aesthetic consultation, providers may also propose alternate devices. Patients must keep these instruments clearly separated from mechanical QAI pens:

• Radiofrequency (RF) Microneedling: RF microneedling devices use arrays of electrodes, also called microneedles, to deliver radiofrequency energy into and under the skin to produce local heating. They are Class II devices cleared through the 510(k) process under a different lookup from product code QAI. Named examples such as Morpheus8 have been classified under product code GEI (electrosurgical cutting and coagulation and accessories); GEI is not QAI, and it is not a delivery authorization. On October 15, 2025, FDA said it is aware of reports of burns, scarring, fat loss, disfigurement, and nerve damage with certain dermatologic or aesthetic uses, including the need for surgical repair or medical intervention. (See: RF microneedling FDA warning: what changed, what did not, and what patients should ask).

• Manual Cosmetic Dermarollers & Stamps: Manual rollers with short, blunt, or densely packed needles that do not penetrate living epidermal or dermal layers, and that claim only exfoliation, improved appearance, smoother look and feel, or a luminous look, generally would not be devices under FDA's November 2020 guidance. They are not a QAI scar or wrinkle authorization and not a delivery authorization.

Cartridge reuse is a third mark, not a delivery yes

When evaluating an appointment, needle cartridge sterility must always be tracked as an independent identity. Conflating cartridge hygiene with delivery clearance creates two dangerous clinical misconceptions:

• The False Equivalence Fallacy: A patient observes the provider unsealing a pristine, sterile single-use cartridge and assumes the procedure is fully FDA-cleared, overlooking the fact that the provider is about to deliver unapproved PRP.

• The Collapsed Identity Fallacy: A patient encounters an unlicensed clinic reusing needle tips and assumes the problem is simply off-label PRP, missing the acute biohazard of bloodborne cross-contamination.

In its October 15, 2025 patient safety advisory, the FDA directly instructed consumers to interrogate their providers regarding needle cartridges:

"Ask your health care provider whether a new microneedle cartridge is used for each patient, and for each treatment session for the same patient. Re-use of the needle cartridge is unsafe and is not consistent with the FDA's review and authorization, even if the cartridge is cleaned."

— U.S. Food and Drug Administration, Information for Patients (October 2025)

The FDA similarly issued explicit directives to healthcare providers: "Do not reuse a microneedling cartridge or use a microneedling cartridge on more than one patient as this could cause transfer of infectious agents." 21 CFR 878.4430 requires performance data on safety features built into the device to protect against cross-contamination, including fluid ingress protection. The SkinPen De Novo summary reports fluid-ingress testing of the cartridge barrier. FDA still tells providers not to reuse a cartridge or use a cartridge on more than one patient, because that could transfer infectious agents, even if the cartridge is cleaned.

For a complete inspection checklist and visual verification guide on cartridge packaging, batch lot codes, and protective sheath barriers, read our companion investigation: Microneedling Cartridges: What Patients Can Ask About Reuse and Sterility.

Candidate suitability, material risks, and what this page does not decide

Microneedling is an invasive medical procedure that creates thousands of controlled puncture wounds through the skin barrier. Even when performed with an authorized Class II pen using cleared mechanical protocols, the treatment carries material clinical risks and strict medical contraindications.

Medical Candidacy and Contraindications

FDA's Microneedling Devices patient page lists situations in which the procedure may not be suitable. Manufacturer Important Safety Information can be narrower: SkinPen-family ISI lists active skin cancer in the treatment area, open wounds, stainless-steel or anesthetic allergy, bleeding disorders, pregnancy or nursing, and current isotretinoin, and repeats that the products are not intended for transdermal delivery. The FDA patient list includes:

• Active Infections: FDA says the procedure may not be suitable if you have an active skin infection, including bacterial, viral, or fungal infection; an infection such as hepatitis or HIV; an active rash on the face; or a current outbreak of cold sores (herpes).

• Bleeding and Vascular Disorders: FDA lists a known history of clotting or bleeding disorders such as hemophilia, and anticoagulant therapies such as warfarin, heparin, or low-dose aspirin.

• Systemic and Immune Conditions: FDA lists immune deficiency or immunosuppression due to medical conditions or medications; uncontrolled diabetes; eczema, psoriasis, vitiligo, or autoimmune disease; and a known malignancy or treatments using chemotherapy, radiotherapy, or steroids.

• Recent Medications: FDA's patient page says the procedure may not be suitable if you are currently taking acne medication with the ingredient isotretinoin or have taken isotretinoin in the past 6 months. SkinPen-family ISI lists current isotretinoin without stating that six-month window. This page does not convert either sentence into a dosing protocol.

• Dermatologic Risk Factors: FDA lists actinic (solar) keratoses, keloid scars or a history of keloid scars, warts, birthmarks or moles in the treatment area, and being tan or planning to be in the sun in the two weeks following the procedure. SkinPen-family ISI separately lists open wounds, sores, or irritated skin in the treatment area.

• Allergies: FDA lists allergy to stainless steel or to topical or local anesthetics, or a history of contact dermatitis to those products.

• Pregnancy and Nursing: Pregnancy or active lactation (safety has not been clinically established in pregnant or nursing women).

Skin of Color Considerations (Fitzpatrick Phototypes IV–VI)

FDA's patient page says the procedure may not be suitable if you have a darker skin type, because there is a risk of darkening or lightening of the skin after the procedure, and some devices authorized for marketing were not studied in subjects with darker skin types. Pigmentation change, including post-inflammatory hyperpigmentation (PIH), is also a labeled less-common risk of authorized uses. This page does not generalize energy-device pigment data onto QAI pens, and it does not give a universal depth or pass-count protocol. Device-specific Fitzpatrick limits belong on that device's summary—for example, Exceed's wrinkle clearance is Fitzpatrick I–III in named facial areas, while MicroPen EVO's facial-acne-scar indication includes all Fitzpatrick types in adults 22 and older.

Material Risks: Authorized Uses vs Unreviewed Combinations

Patients must weigh two distinct risk tiers before proceeding:

• Common Risks of Authorized Uses: FDA's authorized-use common risks include dryness, rough skin, tightness, redness, itching, peeling, discomfort, burning, bruising, bleeding, and crusting. FDA says most side effects occur shortly after a treatment and resolve; the consumer update describes common skin damage as typically going away after a few days or weeks.

• Less Common Material Risks: FDA's less-common authorized-use risks include pigmentation changes (hyperpigmentation or hypopigmentation), lines on the face, reactivation of herpes cold sores, swollen lymph nodes, infection, and stinging or itching when cosmetic products are applied.

• Risks of Unreviewed Combinations: FDA states that the risks associated with off-label uses, combining microneedling devices with other products, or using products that have not been evaluated by FDA are not known. This page does not invent combination complication rates.

Operational Boundaries of This Publication

To maintain strict factual integrity, this publication adheres to firm editorial boundaries:

• No Over-the-Counter or Home Device Endorsement: The FDA has authorized zero microneedling medical devices for over-the-counter (OTC) consumer sale. All cleared QAI systems are prescription-only devices restricted to licensed healthcare facilities.

• No Hair Loss Indications: The FDA has cleared zero microneedling devices for the treatment of alopecia or hair loss.

• No Price or Commercial Auditing: We do not publish commercial add-on pricing averages, clinic fee schedules, or fabricated complication rates.

For further evidence-based analyses of adjacent aesthetic treatments, consult our related publications:

• PRP vs Microneedling: Is the Vampire Facial Worth the Extra Cost? — A comprehensive breakdown of clinical scar trial evidence, cost-benefit trade-offs, and CDC infection-control analyses.

• FDA-Cleared Powered Microneedling Devices: SkinPen vs. Exceed vs. SkinStylus — Detailed technical and indication comparisons across authorized Class II QAI platforms.

• Microneedling Cartridges: What Patients Can Ask About Reuse and Sterility — How to inspect sterile packaging, verify fluid seals, and detect illegal cartridge reuse.

• Is That Aesthetic Device FDA-Cleared? How to Verify Any Machine (and Why CE Doesn't Count) — Step-by-step guidance on searching FDA public access databases for device clearance summaries.

• Off-Label Aesthetic Treatment Consent: Documenting Risk Clearly — Understanding your legal rights and provider responsibilities when treatments deviate from FDA labeling.

• Microneedling vs RF Microneedling: What Each Actually Does to Your Skin — Contrasting pure mechanical puncture with thermal radiofrequency tissue coagulation.

• RF microneedling FDA warning: what changed, what did not, and what patients should ask — Analyzing the October 2025 FDA safety communication regarding burns, facial fat loss, and nerve injury.

• Exosome Treatments in Aesthetics: FDA Status, Evidence, and Why No Product Is Approved — Regulatory reality and safety warnings regarding unapproved topical and injectable exosome products.

• PRP for Skin and Hair: What the Evidence Actually Supports — PRP evidence for skin and hair, not a microneedling delivery authorization.

• Microneedling device adverse events: what 66 FDA MAUDE reports actually show — Reported device events, not this worksheet's delivery identity job.

• FDA-Cleared or Just FDA-Registered? Verifying Aesthetic Device Claims With DJ Fang — Registration is not clearance, and neither is a PRP-delivery authorization.

• How to choose an injector: credentials, supervision, red flags, and what to ask. — Provider vetting, not a ranked clinic list and not a delivery clearance.

Sources

This publication relies exclusively on verified primary regulatory records, statutory codes, official federal safety communications, and manufacturer prescribing information:

1. U.S. Food and Drug Administration. Microneedling Devices. Content current as of October 15, 2025.

2. U.S. Food and Drug Administration. Microneedling Devices: Getting to the Point on Benefits, Risks, and Safety. FDA Consumer Updates, current as of October 15, 2025.

3. U.S. National Archives and Records Administration. 21 CFR § 878.4430: Microneedling device for aesthetic use. Electronic Code of Federal Regulations, June 8, 2018.

4. U.S. Food and Drug Administration. Regulatory Considerations for Microneedling Products: Guidance for Industry and FDA Staff. Document number 1500036, November 10, 2020.

5. U.S. Food and Drug Administration. De Novo Classification Order DEN160029: SkinPen Precision System. Bellus Medical (Crown Aesthetics), March 1, 2018.

6. U.S. Food and Drug Administration. De Novo Decision Summary DEN160029: SkinPen Precision System. Bellus Medical (Crown Aesthetics), 2018.

7. U.S. Food and Drug Administration. 510(k) Premarket Notification K202243: SkinPen Precision System. Crown Aesthetics, 2020.

8. U.S. Food and Drug Administration. 510(k) Premarket Notification K180778: Exceed Microneedling Device. MT.DERM GmbH / amiea med, September 7, 2018.

9. U.S. Food and Drug Administration. 510(k) Premarket Notification K182407: Exceed Microneedling Device. MT.DERM GmbH / amiea med, 2018.

10. U.S. Food and Drug Administration. 510(k) Premarket Notification K200044: SkinStylus SteriLock MicroSystem. Esthetic Education LLC, April 10, 2020.

11. U.S. Food and Drug Administration. 510(k) Premarket Notification K212558: Eclipse MicroPen EVO. Crown Aesthetics / Eclipse Aesthetics, November 24, 2021.

12. U.S. Food and Drug Administration. Product Classification Database: Powered Microneedle Device (Product Code QAI). CDRH Classification Database.

13. U.S. Food and Drug Administration. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication. Center for Devices and Radiological Health, October 15, 2025.

14. U.S. Food and Drug Administration. 510(k) Premarket Notification Summary BK241042: Illuminate PRP. CBER Automated Blood Cell Separator (Product Code ORG), 2024.

15. Crown Aesthetics. ProGen Platelet-Rich Plasma System Intended Use. Crown Aesthetics product documentation, retrieved September 2026.

16. Revance. SkinPen Precision Elite, SkinPen Precision, and MicroPen EVO Indications and Important Safety Information. Revance Therapeutics, 2025.